Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Impact of Acridine Orange in Patients With Local Recurrent Soft Tissue Sarcoma

HIROYUKI TSUCHIE, MAKOTO EMORI, NAOHISA MIYAKOSHI, KYOJI OKADA, HIROYUKI NAGASAWA, YASUTAKA MURAHASHI, EMI MIZUSHIMA, JUNYA SHIMIZU, TOSHIHIKO YAMASHITA and YOICHI SHIMADA
In Vivo September 2020, 34 (5) 2745-2750; DOI: https://doi.org/10.21873/invivo.12097
HIROYUKI TSUCHIE
1Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for HIROYUKI TSUCHIE
  • For correspondence: tuchikiti@yahoo.co.jp
MAKOTO EMORI
2Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOHISA MIYAKOSHI
1Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KYOJI OKADA
3Department of Physical Therapy, Akita University Graduate School of Health Sciences, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI NAGASAWA
1Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUTAKA MURAHASHI
2Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EMI MIZUSHIMA
2Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNYA SHIMIZU
2Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIHIKO YAMASHITA
2Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOICHI SHIMADA
1Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Local recurrence in soft tissue sarcoma (STS) is a risk factor of worse prognosis. Although a few studies have shown that adjuvant therapy with acridine orange (AO) is effective for local control of primary STS, there have been no reports examining its effectiveness for local recurrence. Patients and Methods: This retrospective study included 36 patients with first local recurrence of STS. Of them, 23 patients received wide excision without AO therapy (Wide group); the other 13 patients received marginal excision with AO therapy (AO group). We compared re-recurrence rates between these two groups. Results: The total re-recurrence rate was 43.5% in the Wide group and 46.2% in the AO group. There was no significant difference in local re-recurrence-free survival and overall survival between the two groups. Conclusion: Adjuvant AO therapy combined with a marginal excision suppresses local re-recurrence rates of individuals with local STS recurrence.

  • Acridine orange
  • local recurrence
  • soft tissue sarcoma

Soft tissue sarcoma (STS) is relatively rare compared with other types of cancer. Radical resection with an adequate margin is important in the treatment of STS for the prevention of local recurrence. However, when tumors are in contact with important tissues such as major nerves or blood vessels, removing these important tissues can cause serious dysfunction. If resection is conducted in the area where the tumor is in contact with the tissue, the recurrence rate increases. Local recurrence itself is a risk factor of local re-recurrence and a worse prognosis; once local recurrence occurs, it is more difficult to control the STS (1).

Kusuzaki et al. were the first to report the effectiveness of acridine orange (AO) treatment as an adjuvant therapy in soft tissue sarcomas in various different studies (2-8). AO accumulates in acidic environments. As sarcoma cells have many large acidic vesicles, AO specifically binds to malignant tumors and immediately accumulates in tumor cells after local administration (9-13). AO has a strong cell-destructive effect on tumor cells after a single session of blue light excitation or low-dose radiation, which kills residual tumor cells after tumor resection.

Several studies have shown that adjuvant therapy with AO is effective on the local control of primary STS (2-8, 14). However, there have been no reports examining the effectiveness of AO treatment for local recurrence cases of STS. The aim of this study was to clarify the efficacy of AO therapy by comparing marginal excisions with adjuvant AO therapy and wide excisions in STS patients with local recurrence.

Patients and Methods

Patients. Forty-two STS patients with local recurrence involving the extremities or trunk were treated with surgical resection, with the exception of amputation surgery, conducted in the Akita University Hospital and Sapporo Medical University Hospital between January 1994 and December 2019. They had not developed distant metastases prior to the surgery for the local recurrence. We defined marginal excision as a resection through the capsule of the tumor and intralesional excision as resection through the tumor; we excluded 4 cases of marginal excision without AO therapy and 2 cases of intralesional excision in this study. Consequently, 36 patients with local STS recurrence treated with wide excision or marginal excision with AO therapy, with a mean age of 66.9 years (range=32-88 years), were included in this study. Twenty-three of the 36 patients underwent wide excision on the recurrent lesion (Wide group), and the other 13 patients were treated by marginal excision with AO therapy on the recurrent lesions (AO group). Marginal excision with AO therapy was performed on patients when the recurrent tumor was contacting major nerves or vessels, bones, and/or major organs without any signs of massive invasion upon pre-surgery imaging evaluation.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Comparison of patient characteristics between those in the wide excision and those in the acridine orange groups.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Univariate logistic regression analysis of factors affecting the local “re-recurrence” of patients.

This study was approved by the Institutional Review Board for Clinical Research at Akita University (approval number: 221), and informed consent was obtained from all patients.

Data variables and definitions. Information collected from the patients included: age, gender, histological diagnosis of the tumor, anatomical location of the tumor, primary and recurrence tumor sizes, histological grade, stage of the primary tumor, treatments for the primary and recurrence tumors, local re-recurrence, distant relapse, time to the local recurrence, follow-up period, and outcomes. The stage of the primary tumor was determined based on the staging system of the American Joint Committee on Cancer (AJCC), 7th edition (15). Histological grade of the specimens was classified using the French Federation of Cancer Center Sarcoma Group (FNCLCC) classification. This classification is based on the mitotic index, necrotic extension, and histological differentiation of the tumor (16). In the absence of death, the date of the last follow-up was defined as the end of the follow-up period. The local re-recurrence-free survival (LRRS) was defined as the period from the surgery for the recurrent tumor till the diagnosis of local re-recurrence. Overall survival (OS) was defined as the period from the date of the primary tumor diagnosis to the last follow-up or death. As there were no deaths due to postoperative complications in this study, we defined the deaths from STS as “died of disease” (DOD). Cases were regarded to have a surgical indication if all lesions, including distant metastases, were able to be excised.

Procedures for AO therapy. We conducted AO therapy, including photodynamic surgery (PDS), photodynamic therapy (PDT), and radiodynamic therapy (RDT), according to methods previously reported (2-7). After marginal excision of STS, a 1 μg/ml solution of AO (Sigma Aldrich Co, St Louis, MO, USA) was sprayed around the major nerves, vessels, and organs. Microscopic curettage was conducted using an ultrasonic surgical knife (Olympus Co. Ltd., Tokyo, Japan), a high-power xenon lamp (500 mW; >100,000 lux), and special interference and resorption filters (450-490 nm) to select only the blue light emitted by a xenon lamp (PDS). Administration of the AO-fluid and microscopic curettage was repeated until the green AO-fluorescence area marking the remaining tumor cells had disappeared completely. PDT was followed by PDS. PDT was subsequently applied to the resected area of the tumor by illuminating it with >100,000 lux of unfiltered light from a xenon lamp for 10 min. The final step, RDT, was performed in patients who agreed to undergo RDT. After closure of the surgical wound, without washing of the AO solution, single-session radiotherapy with 5 Gy was immediately administered to the resected area. Although it was policy to conduct RDT in all cases, we did not conduct RDT when patients did not agree to it or when the radiation room was not available immediately after surgery.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Kaplan-Meier local re-recurrence-free survival curves based on the use of acridine orange in all patients. There was no significant difference between the two groups. AO: Acridine orange.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Kaplan-Meier overall survival curves based on the use of acridine orange in all patients. There was no significant difference between the two groups. AO: Acridine orange.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Univariate and multivariate analysis of factors affecting prognosis.

Statistical analysis. We compared the clinical courses and results between the Wide and the AO groups, and analyzed the factors affecting the local re-recurrence and prognosis after the recurrence.

All continuous variables were expressed as means±standard deviations (SD). Student's t-tests, Welch t-tests, and Chi Squared (χ2) tests were used to compare characteristics between the two groups. The curves for LRRS and OS were drawn using the Kaplan-Meier method, and differences were analyzed using the generalized Wilcoxon test. A Cox proportional hazards model was used to identify the factors associated with local re-recurrence and prognosis. Probability (p) values less than 0.05 were considered significant.

Results

The mean follow-up period for all patients was 82.4±57.8 months (range=9-284 months). The histological diagnoses were myxofibrosarcoma in 12 cases (33.3%), undifferentiated pleomorphic sarcoma in 8 cases (22.2%), dedifferentiated liposarcoma in 4 cases (11.1%), myxoid liposarcoma in 4 cases (11.1%), synovial sarcoma in 2 cases (5.6%), leiomyosarcoma in 2 cases (5.6%), and 1 case each (2.8%) of pleomorphic liposarcoma, low grade fibromyxosarcoma, extraskeletal myxoid chondrosarcoma, and alveolar soft-part sarcoma. The sites of the primary lesions were in the extremities in 19 patients (52.8%) and in axial sites in 17 patients (47.2%). The mean tumor size at the primary lesion and recurrence was 81.6±60.7 mm (range=18-250 mm) and 51.2±27.4 mm (range=14-130 mm), respectively. The FNCLCC classifications were grade I for 6 patients, grade II for 9 patients, grade III for 20 patients, and unknown for 1 patient. According to the AJCC staging system, the disease stages of the primary tumor were IA for 2 patients, stage IB for 4 patients, stage IIA for 14 patients, stage IIB for 2 patients, stage III for 13 patients, and unknown for 1 patient. Neoadjuvant chemotherapies in the perioperative period, involving doxorubicin and ifosfamide, were administered to 2 patients for the primary tumor and 2 patients for the recurrent lesions. Adjuvant radiotherapy was performed for 4 patients in the primary perioperative period. Adequate tumor-free margins for the primary tumor were achieved for 16 patients (44.4%). The mean period until the appearance of local recurrence for all patients was 25.6±20.6 months (range=2-68 months). In the AO group, the combined treatment of PDS and PDT for the recurrent lesion was performed in 11 (84.6%) patients; PDS, PDT, and RDT for the recurrent lesion were performed in 2 (15.4%) patients. A total of 16 patients (44.4%) developed local re-recurrence. The number of local recurrences, including the first recurrence within the follow-up period, was 1.8±1.2 times (range=1-5 times). Ten patients (27.8%) developed metastases after the initial local recurrence surgery. At the end of the study, no evidence of disease was found in 22 patients, 5 patients were classified as alive with disease, and 9 patients died of disease. No patients died because of complications during the perioperative period.

There were no significant differences in clinical information between the Wide group and the AO group (Table I). The 5-year local re-recurrence rate was 47.1% in the Wide group and 33.3% in the AO group; the total re-recurrence rate was 43.5% in the Wide group and 46.2% in the AO group. There were no significant differences in the Kaplan-Meier curves for local re-recurrence survival and overall survival between the two groups (Figures 1 and 2). In the univariate logistic analysis, which investigated factors associated with the local re-recurrence, only male gender was identified as a risk factor for local re-recurrence (p<0.05) (Table II). In univariate analysis, which investigated factors associated with prognosis, male gender, tumor size at the recurrence, and metastasis after the surgery for the recurrence were identified as risk factors for poor prognosis. Multivariate analysis identified the tumor size at recurrence and metastasis after the surgery as risk factors for poor prognosis (p<0.05) (Table III).

Discussion

Clinical results of marginal excision with AO have been reported to be equivalent to wide excision (2-8). In our previous research, we reported that local control of STS by marginal excision with AO therapy was significantly better than that of marginal excision without adjuvant therapy (14). Our current study showed that a marginal excision with AO can provide local control equivalent to a wide excision, even in local and aggressive recurrent STS cases. Marginal excision with AO requires less tissue to be resected than wide excision, and functional preservation can be expected. Due to the suppressive effects on recurrence and preservation of postoperative function, marginal excision with AO therapy is considered to be an effective treatment.

In the present study, the local re-recurrence rate was relatively high; 43.5% after the extensive resection and 46.2% after the marginal excision with AO. Previous reports of local re-recurrent rates of STS ranged from 20-47%, and the results of surgical treatment for local recurrence generally tended to be worse than the results of the initial surgical treatment (1, 17-24). Among these reports, Sugiura et al. analyzed re-recurrence in STS cases, and reported a low re-recurrence rate (20%). Furthermore, they reported that a resection with a margin of 2 cm or more has a local control rate of 87.2% (17); they had also removed all the scar tissue in the resection area of the initial operation. In some of the present cases, we did not perform sufficient excision of the scar tissue after the initial excision. In addition, the Wide group in the present study included cases whose resection margin is not marginal but less than 2 cm. The lack of a stricter definition of the surgical margin may have led to the present high re-recurrence rate. Although our research shows the effectiveness of adjuvant AO therapy, in cases of local recurrence that was difficult to control locally, AO therapy did not show more efficacy than extensive excision.

This study identified male gender as a risk factor for local re-recurrence. Risk factors for local re-recurrence, such as the excision margin, occurrence in the upper limbs, and no adjuvant therapy, have been reported (1, 17, 18). In our study, there were no cases of adjuvant radiotherapy in the perioperative period of local recurrence, and few patients received chemotherapy. The relatively low local control rate in our cases may have been affected by not administering adjuvant therapy. However, Torres et al. also reported that adjuvant radiotherapy for local recurrence did not show effectiveness (18). Because there are still conflicting opinions, more cases should be examined in the future to clarify the risk factors of re-recurrence.

The risk factors of prognosis in the cases of local recurrence reported in past studies include the size of the locally recurrent tumor, male gender, and the tumor being histologically high grade (1). In our study, the size of locally recurrent tumor was identified as a poor prognostic factor, along with the appearance of distant metastases. This result shows that a careful follow-up after the first operation is imperative in order to identify local recurrences early.

One of the main limitations of this study was the small number of patients. Several factors may have led to biases, such as histological malignancy, size, and location of the tumor; a larger number of patients are needed to sufficiently analyze these factors. Although we initially targeted more patients, by refining our cases to exclude patients with distant metastasis or amputation, the number of cases in this study was reduced.

This study shows that the inhibitory effect of a marginal excision with adjuvant AO therapy on local re-recurrence of local recurrent STS is just as efficacious as a wide excision. The size of the locally recurrent tumor, and distant metastasis after the surgery for the recurrent lesion affect prognosis, which demonstrates the importance of these factors in the careful follow-up of patients after the first operation.

Footnotes

  • Authors' Contributions

    All Authors were involved in the planning and revising for this research; Tsuchie H, Nagasawa H, Emori M, Murahasi Y, Mizushima E, and Shimizu J collected the clinical data; Tsuchie H analyzed the raw data; Tsuchie H wrote this manuscript; Miyakoshi N, Okada K, Yamashita Y, and Shimada Y reviewed this manuscript.

  • This article is freely accessible online.

  • Conflicts of Interest

    This work was supported by the Japan Orthopedics and Traumatology Foundation, Inc. under Grant (number: 390). Tsuchie H. reports receiving funding from a research grant foundation that may be affected by the research reported in the enclosed paper.

  • Received April 13, 2020.
  • Revision received April 24, 2020.
  • Accepted April 27, 2020.
  • Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Eilber FC,
    2. Rosen G,
    3. Nelson SD,
    4. Selch M,
    5. Dorey F,
    6. Eckardt J,
    7. Eilber FR
    : High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg 237(2): 218-226, 2003. PMID: 12560780. DOI: 10.1097/01.SLA.0000048448.56448.70
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kusuzaki K,
    2. Murata H,
    3. Matsubara T,
    4. Miyazaki S,
    5. Okamura A,
    6. Seto M,
    7. Matsumine A,
    8. Hosoi H,
    9. Sugimoto T,
    10. Uchida A
    : Clinical trial of photodynamic therapy using acridine orange with/without low dose radiation as new limb salvage modality in musculoskeletal sarcomas. Anticancer Res 25(2B): 1225-1235, 2005. PMID: 15865070.
    OpenUrlAbstract/FREE Full Text
    1. Nakamura T,
    2. Kusuzaki K,
    3. Matsubara T,
    4. Matsumine A,
    5. Murata H,
    6. Uchida A
    : A new limb salvage surgery in cases of high-grade soft tissue sarcoma using photodynamic surgery, followed by photo- and radiodynamic therapy with acridine orange. J Surg Oncol 97(6): 523-528, 2008. PMID: 18348188. DOI: 10.1002/jso.21025
    OpenUrlPubMed
    1. Matsubara T,
    2. Kusuzaki K,
    3. Matsumine A,
    4. Murata H,
    5. Satonaka H,
    6. Shintani K,
    7. Nakamura T,
    8. Hosoi H,
    9. Iehara T,
    10. Sugimoto T,
    11. Uchida A
    : A new therapeutic modality involving acridine orange excitation by photon energy used during reduction surgery for rhabdomyosarcomas. Oncol Rep 21(1): 89-94, 2009. PMID: 19082447.
    OpenUrlPubMed
    1. Matsubara T,
    2. Kusuzaki K,
    3. Matsumine A,
    4. Murata H,
    5. Nakamura T,
    6. Uchida A,
    7. Sudo A
    : Clinical outcomes of minimally invasive surgery using acridine orange for musculoskeletal sarcomas around the forearm, compared with conventional limb salvage surgery after wide resection. J Surg Oncol 102(3): 271-275, 2010. PMID: 20740586. DOI: 10.1002/jso.21602
    OpenUrlPubMed
    1. Matsubara T,
    2. Kusuzaki K,
    3. Matsumine A,
    4. Nakamura T,
    5. Sudo A
    : Can a less radical surgery using photodynamic therapy with acridine orange be equal to a wide-margin resection? Clin Orthop Relat Res 471(3): 792-802, 2013. PMID: 23008027. DOI: 10.1007/s11999-012-2616-9
    OpenUrlPubMed
  3. ↵
    1. Nakamura T,
    2. Kusuzaki K,
    3. Matsubara T,
    4. Murata H,
    5. Hagi T,
    6. Asanuma K,
    7. Sudo A
    : Long-term clinical outcome in patients with high-grade soft tissue sarcoma who were treated with surgical adjuvant therapy using acridine orange after intra-lesional or marginal resection. Photodiagnosis Photodyn Ther 23: 165-170, 2018. PMID: 29885811. DOI: 10.1016/j.pdpdt.2018.06.001
    OpenUrl
  4. ↵
    1. Kusuzaki K,
    2. Takai T,
    3. Yoshimura H,
    4. Inoue K,
    5. Takai S,
    6. Baldini N
    : Clinical Trial of Radiotherapy After Intravenous Injection of Acridine Orange for Patients with Cancer. Anticancer Res 38(1): 481-489, 2018. PMID: 29277813. DOI: 10.21873/anticanres.12248
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Kusuzaki K,
    2. Aomori K,
    3. Suginoshita T,
    4. Minami G,
    5. Takeshita H,
    6. Murata H,
    7. Hashiguchi S,
    8. Ashihara T,
    9. Hirasawa Y
    : Total tumor cell elimination with minimum damage to normal tissues in musculoskeletal sarcomas following photodynamic therapy with acridine orange. Oncology 59(2): 174-180, 2000. PMID: 10971178. DOI: 10.1159/000012156
    OpenUrlCrossRefPubMed
    1. Kusuzaki K,
    2. Murata H,
    3. Takeshita H,
    4. Hashiguchi S,
    5. Nozaki T,
    6. Emoto K,
    7. Ashihara T,
    8. Hirasawa Y
    : Intracellular binding sites of acridine orange in living osteosarcoma cells. Anticancer Res 20(2A): 971-975, 2000. PMID: 10810383.
    OpenUrlPubMed
    1. Kusuzaki K,
    2. Suginoshita T,
    3. Minami G,
    4. Aomori K,
    5. Takeshita H,
    6. Murata H,
    7. Hashiguchi S,
    8. Ashihara T,
    9. Hirasawa Y
    : Fluoro-visualization effect of acridine orange on mouse osteosarcoma. Anticancer Res 20(5A): 3019-3024, 2000. PMID: 11062717.
    OpenUrlPubMed
    1. Kusuzaki K,
    2. Takeshita H,
    3. Murata H,
    4. Gebhardt MC,
    5. Springfield DS,
    6. Mankin HJ,
    7. Ashihara T,
    8. Hirasawa Y
    : Polyploidization induced by acridine orange in mouse osteosarcoma cells. Anticancer Res 20(2A): 965-970, 2000. PMID: 10810382.
    OpenUrlPubMed
  6. ↵
    1. Matsubara T,
    2. Kusuzaki K,
    3. Matsumine A,
    4. Shintani K,
    5. Satonaka H,
    6. Uchida A
    : Acridine orange used for photodynamic therapy accumulates in malignant musculoskeletal tumors depending on pH gradient. Anticancer Res 26(1A): 187-193, 2006. PMID: 16475697.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Tsuchie H,
    2. Emori M,
    3. Miyakoshi N,
    4. Nagasawa H,
    5. Okada K,
    6. Murahashi Y,
    7. Mizushima E,
    8. Shimizu J,
    9. Yamashita T,
    10. Shimada Y
    : Impact of acridine orange in patients with soft tissue sarcoma treated with marginal resection. Anticancer Res 39(11): 6365-6372, 2019. PMID: 31704869. DOI: 10.21873/anticanres.13849
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Edge SB,
    2. Compton CC
    : AJCC cancer staging handbook. 7th ed, Springer, New York; Springer 2010.
  9. ↵
    1. Coindre JM,
    2. Terrier P,
    3. Bui NB,
    4. Bonichon F,
    5. Collin F,
    6. Le Doussal V,
    7. Mandard AM,
    8. Vilain MO,
    9. Jacquemier J,
    10. Duplay H,
    11. Sastre X,
    12. Barlier C,
    13. Henry-Amar M,
    14. Macé-Lesech J,
    15. Contesso G
    : Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 14(3): 869-877, 1996. PMID: 8622035. DOI: 10.1200/JCO.1996.14.3.869
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Sugiura H,
    2. Nishida Y,
    3. Nakashima H,
    4. Yamada Y,
    5. Tsukushi S,
    6. Yamada K
    : Surgical procedures and prognostic factors for local recurrence of soft tissue sarcomas. J Orthop 19(1): 141-149, 2014. PMID: 24081391. DOI: 10.1007/s00776-013-0469-z
    OpenUrl
  11. ↵
    1. Torres MA,
    2. Ballo MT,
    3. Butler CE,
    4. Feig BW,
    5. Cormier JN,
    6. Lewis VO,
    7. Pollock RE,
    8. Pisters PW,
    9. Zagars GK
    : Management of locally recurrent soft-tissue sarcoma after prior surgery and radiation therapy. Int J Radiat Oncol Biol Phys 67(4): 1124-1129, 2007. PMID: 17208389. DOI: 10.1016/j.ijrobp.2006.10.036
    OpenUrlCrossRefPubMed
    1. Ramanathan RC,
    2. A'Hern R,
    3. Fisher C,
    4. Thomas JM
    : Prognostic index for extremity soft tissue sarcomas with isolated local recurrence. Ann Surg Oncol 8(4): 278-289, 2001. PMID: 11352300. DOI: 10.1007/s10434-001-0278-z
    OpenUrlCrossRefPubMed
    1. Trovik CS
    : Scanadinavian Sarcoma Group Project. Local recurrence of soft tissue sarcoma. A Scandinavian Sarcoma Group Project. Acta Orthop Scand Suppl 72(300): 1-31, 2001. PMID: 11381580.
    OpenUrlCrossRefPubMed
    1. Pearlstone DB,
    2. Janjan NA,
    3. Feig BW,
    4. Yasko AW,
    5. Hunt KK,
    6. Pollock RE,
    7. Lawyer A,
    8. Horton J,
    9. Pisters PW
    : Re-resection with brachytherapy for locally recurrent soft tissue sarcoma arising in a previously radiated field. Cancer J Sci Am 5(1): 26-33, 1999. PMID: 10188058.
    OpenUrlPubMed
    1. Karakousis CP,
    2. Proimakis C,
    3. Rao U,
    4. Velez AF,
    5. Driscoll DL
    : Local recurrence and survival in soft-tissue sarcomas. Ann Surg Oncol 3(3): 255-260, 1996. PMID: 8726180. DOI: 10.1007/bf02306280
    OpenUrlCrossRefPubMed
    1. Robinson M,
    2. Barr L,
    3. Fisher C,
    4. Fryatt I,
    5. Stotter A,
    6. Harmer C,
    7. Wiltshaw E,
    8. Westbury G
    : Treatment of extremity soft tissue sarcomas with surgery and radiotherapy. Radiother Oncol 18(3): 221-233, 1990. PMID: 2217870. DOI: 10.1016/0167-8140(90)90058-5
    OpenUrlCrossRefPubMed
  12. ↵
    1. Giuliano AE,
    2. Eilber FR,
    3. Morton DL
    : The management of locally recurrent soft-tissue sarcoma. Ann Surg 196(1): 87-91, 1982. PMID: 7092358. DOI: 10.1097/00000658-198207000-00018
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

In Vivo: 34 (5)
In Vivo
Vol. 34, Issue 5
September-October 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Acridine Orange in Patients With Local Recurrent Soft Tissue Sarcoma
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Impact of Acridine Orange in Patients With Local Recurrent Soft Tissue Sarcoma
HIROYUKI TSUCHIE, MAKOTO EMORI, NAOHISA MIYAKOSHI, KYOJI OKADA, HIROYUKI NAGASAWA, YASUTAKA MURAHASHI, EMI MIZUSHIMA, JUNYA SHIMIZU, TOSHIHIKO YAMASHITA, YOICHI SHIMADA
In Vivo Sep 2020, 34 (5) 2745-2750; DOI: 10.21873/invivo.12097

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Impact of Acridine Orange in Patients With Local Recurrent Soft Tissue Sarcoma
HIROYUKI TSUCHIE, MAKOTO EMORI, NAOHISA MIYAKOSHI, KYOJI OKADA, HIROYUKI NAGASAWA, YASUTAKA MURAHASHI, EMI MIZUSHIMA, JUNYA SHIMIZU, TOSHIHIKO YAMASHITA, YOICHI SHIMADA
In Vivo Sep 2020, 34 (5) 2745-2750; DOI: 10.21873/invivo.12097
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy
  • Forensic Medical Examination After Sexual Violence: Implications Based on Victims’ Perceptions
  • Albumin–derived Neutrophil-to-Lymphocyte Ratio Score as a Marker of Nivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study
Show more Clinical Studies

Similar Articles

Keywords

  • Acridine orange
  • local recurrence
  • soft tissue sarcoma
In Vivo

© 2023 In Vivo

Powered by HighWire